💊 Health Futures #37

Happy Monday 👋

This week's health news features Targeted Chronic Disease Management, Diagnosis Technology, and Clinical Trials. In Targeted Chronic Disease Management, Novo Nordisk showed promising results in a Phase IIa trial for the obesity drug ‘monlunabant’. The pharmaceutical company plans to conduct further studies to assess its safety and efficacy. In diagnosis technology, GE HealthCare launched Venue Sprint, a new portable ultrasound system designed to meet the demand for point-of-care ultrasound and offers high-quality imaging, AI-enabled tools, and intuitive documentation tools. In clinical trials, Summit Therapeutics improved efficacy over Merck’s Keyturda in phase III trials. The drug's dual mechanism targeting PD-1 and VEGF could disrupt the oncology market, similar to Regeneron's Eylea. In health funding, Telix Pharmaceuticals acquired RLS Radiopharmacies for $230M expanding its manufacturing and distribution footprint in North America.

🎯 Targeted Chronic Disease Management

🧪 Novo Nordisk showed promising results in a Phase IIa trial for obesity. In the trial, patients treated with ‘monlunabant,’ a cannabinoid receptor 1 inverse agonist, experienced significant weight loss compared to placebo. 

💊 Halia Therapeutics announced positive preclinical results for HT-6184 combined with semaglutide in treating obesity. HT-6184 targets inflammation, a key driver of obesity-related metabolic dysfunction.

🩸 New blood test to identify diabetes risk in children. A new blood test helped identify children at risk of obesity-related conditions by assessing a broader range of lipid molecules.

🌐 Diagnosis Technology

🤖 Huawei teamed up with partners to launch the Medical Technology Digitalization 2.0 Solution. The solution uses AI-assisted diagnosis and intelligent quality control to improve the quality and efficiency of healthcare services.

👶 GE HealthCare launched the Venue Sprint, a new portable ultrasound system.  The device is designed to meet the growing demand for point-of-care ultrasound and offers high-quality imaging, AI-enabled tools, and intuitive documentation tools.

🐟 XpertDox partners with Blue Fish Pediatrics.  This partnership aims to implement XpertCoding, an AI-powered medical coding platform to enhance efficiency, accuracy, and clinical documentation at Blue Fish Pediatrics' clinics.

🧬 Clinical Trials

🔬 Sanofi's ‘tolebrutinib’ showed promising results in a Phase III trial for non-relapsing secondary progressive multiple sclerosis. The drug delayed the onset of disability progression by 31% in patients with this condition.

🧫 Proteomics International reported positive results for the PromarkerEso oesophageal cancer test. This test is targeted for the early detection and treatment of the illness, a predominant form of esophageal cancer.

🎗️ Summit Therapeutics outperformed Merck's cancer drug in Phase III trials. Summit drug, ‘ivonescimab’ showed improved efficacy over Merck’s Keytruda targeting both PD-1 and VEGF. 

💰 Deals of the Week

📻 Telix Pharmaceuticals acquired RLS Radiopharmacies for $230M. The acquisition intends to meet the current growing demand for diagnostic and therapeutic radiopharmaceuticals.

🏥 Alan, a France-based health insurer, raised $192M in Series F funding at a $4.5B valuation. The company plans to use the funds to expand operations and development efforts.

🧬 Vicebio, a biopharmaceutical company, raised $100M in Series B funding. The company intends to accelerate the development of multivalent respiratory virus vaccines using proprietary molecular clamp technology.

💊 Ahammune Biosciences raised $5M in a Series A funding round led by early-stage venture fund pi Ventures. The capital is used to help conduct Phase II human clinical trials for its vitiligo drug candidate.

💉 Helix Labs secured $2M in Pre-Seed funding. The company plans to use the funds to expand operations and its development efforts.

Thank you for reading. Have a great week ahead!
Have some feedback or suggestions? Let us know at hello@holoniq.com